(+)-3-(isopropoxy-d7)-17-ethoxycarbonyl-(9α,13α,14α)-morphinan | 1216910-31-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (+)-3-(isopropoxy-d7)-17-ethoxycarbonyl-(9α,13α,14α)-morphinan
• 英文别名: ethyl (1S,9S,10S)-4-(1,1,1,2,3,3,3-heptadeuteriopropan-2-yloxy)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-17-carboxylate
• CAS: 1216910-31-4
• 化学式: C₂₂H₃₁NO₃
• 分子量: 364.437
• InChiKey: HRWZZKMNINYROY-BNGSVQPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+)-3-(isopropoxy-d7)-17-ethoxycarbonyl-(9α,13α,14α)-morphinan 在 lithium aluminium deuteride 作用下， 以 四氢呋喃 为溶剂， 生成 (+)-3-(isopropoxy-d7)-17-(methyl-d3)-(9α,13α,14α)-morphinan
  参考文献：
  名称：

  [EN] MORPHINAN COMPOUNDS
  [FR] COMPOSÉS DU MORPHINANE

  摘要：

  本发明涉及新型的吗啡喃化合物及其可药用盐。本发明还提供了包含本发明化合物的组合物，以及在使用σ1受体激动剂且具有NMDA拮抗活性的药物治疗方法中使用该组合物来治疗疾病和状况。

  公开号：

  WO2010033801A1
• 作为产物：
  描述：

  (+)-17-ethylcarbamate-3-hydroxy-(9α,13α,14α)-morphinan 、 2-碘丙烷-d7 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以85%的产率得到(+)-3-(isopropoxy-d7)-17-ethoxycarbonyl-(9α,13α,14α)-morphinan
  参考文献：
  名称：

  [EN] MORPHINAN COMPOUNDS
  [FR] COMPOSÉS DU MORPHINANE

  摘要：

  本发明涉及新型的吗啡喃化合物及其可药用盐。本发明还提供了包含本发明化合物的组合物，以及在使用σ1受体激动剂且具有NMDA拮抗活性的药物治疗方法中使用该组合物来治疗疾病和状况。

  公开号：

  WO2010033801A1

文献信息

• COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
  申请人：Concert Pharmaceuticals, Inc.

  公开号：US20160143902A1

  公开（公告）日：2016-05-26

  Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.

  本文提供了包含根据公式I或公式II的右美沙芬类似物或其药学上可接受的盐之一，以及辅助剂，例如抗抑郁药物，如选择性5-羟色胺和去甲肾上腺素再摄取抑制剂；5-羟色胺、去甲肾上腺素、多巴胺再摄取抑制剂；去甲肾上腺素、多巴胺再摄取抑制剂；单胺氧化酶抑制剂；选择性5-羟色胺再摄取抑制剂；三环抗抑郁药物或其中任何一种的药学上可接受的盐的组合物。这些组合物在假性球麻痹、神经痛、神经退行性疾病、脑损伤等治疗中非常有用。
• MORPHINAN COMPOUNDS
  申请人：Graham Philip B.

  公开号：US20110257214A1

  公开（公告）日：2011-10-20

  This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.
• COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
  申请人：Thomas Amanda

  公开号：US20120053169A1

  公开（公告）日：2012-03-01

  Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt of either of the foregoing and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.
• [EN] MORPHINAN COMPOUNDS<br/>[FR] COMPOSÉS DU MORPHINANE
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2010033801A1

  公开（公告）日：2010-03-25

  This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

  本发明涉及新型的吗啡喃化合物及其可药用盐。本发明还提供了包含本发明化合物的组合物，以及在使用σ1受体激动剂且具有NMDA拮抗活性的药物治疗方法中使用该组合物来治疗疾病和状况。